Moderna (MRNA) Other Working Capital Changes: 2018-2025
Historic Other Working Capital Changes for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$42.0 million.
- Moderna's Other Working Capital Changes rose 87.00% to -$42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 85.53%. This contributed to the annual value of -$439.0 million for FY2024, which is 78.69% up from last year.
- According to the latest figures from Q3 2025, Moderna's Other Working Capital Changes is -$42.0 million, which was down 121.43% from $196.0 million recorded in Q2 2025.
- Moderna's 5-year Other Working Capital Changes high stood at $3.7 billion for Q1 2021, and its period low was -$1.6 billion during Q4 2021.
- For the 3-year period, Moderna's Other Working Capital Changes averaged around -$217.4 million, with its median value being -$160.0 million (2023).
- Over the last 5 years, Moderna's Other Working Capital Changes had its largest YoY gain of 91,550.00% in 2021, and its largest YoY loss of 595.74% in 2021.
- Quarterly analysis of 5 years shows Moderna's Other Working Capital Changes stood at -$1.6 billion in 2021, then rose by 8.77% to -$1.5 billion in 2022, then surged by 39.50% to -$887.0 million in 2023, then spiked by 70.46% to -$262.0 million in 2024, then spiked by 87.00% to -$42.0 million in 2025.
- Its last three reported values are -$42.0 million in Q3 2025, $196.0 million for Q2 2025, and -$46.0 million during Q1 2025.